Further evidence of clinical benefit associated with participation in phase I oncology trials

British Journal of Cancer

Volumn 98, Issue 6, 2008, Pages 1021-1022

  Markman, M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; IMATINIB; PACLITAXEL;

ADVANCED CANCER; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DRUG FATALITY; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; METASTASIS; NEOPLASM; OVARY CANCER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PATIENT PARTICIPATION; TREATMENT OUTCOME;

EID: 40849126865     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604206     Document Type: Editorial

References (10)

1. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W (1987) False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep 17(2): 20-24
2. Arkenau H-T, Olmos D, Ang JE, de Bono J, Judson I, Kaye S (2008) Clinical outcome and prognostic factors for patients treated within the context of a phase-1 study: the Royal Marsden Hospital experience. Br J Cancer 98: 1029-1033
3. Bookman MB, McGuire III WP, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH, Ozols RF (1996) Carboplatin and paclitaxel in ovarian carcinoma: a phase 1 study of the Gynecologic Oncology Group. J Clin Oncol 14: 1895-1902
4. Decoster G, Stein G, Holdener EE (1990) Responses and toxic deaths in phase 1 clinical trials. Ann Oncol 1: 175-181
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 244: 1031-1037
6. Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R (1986) Therapeutic response in phase 1 trials of antineoplastic agents. Cancer Treat Rep 70: 1105-1115
7. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ, Grady C (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352: 895-904
8. Itoh K, Sasaki Y, Miyata Y, Fujii H, Ohtsu T, Wakita H, Igarashi T, Abe K (1994) Therapeutic response and potential pitfalls in phase 1 clinical trials of anticancer agents conducted in Japan. Cancer Chemother Pharmacol 34: 451-454
9. Miller M (2000) Phase 1 cancer trials: a collusion of misunderstanding. Hastings Cent Rep 30(4): 34-42
10. Von Hoff DD, Turner J (1991) Response rates, duration of response, and dose response effects in phase 1 studies of antineoplastics. Invest New Drugs 9: 115- 122